Influenza

Final thoughts are provided as the panelists consider opportunities in the field of influenza vaccination.

The panel provides opinions on the incorporation of vaccine awareness and administration from public and state levels.

Although there are no expected shortages of this season’s flu vaccines, knowing where to get help just in case is essential.

Key opinion leaders discuss disparities across varying patient demographics concerning access to vaccines.

The expert panel identifies patient populations who can benefit most from influenza vaccination.

Address vaccine hesitancy at your pharmacy to encourage patients and their families to get vaccinated against COVID-19, flu, and more.

Keep your pharmacy vaccine-ready for your youngest patients with the most current influenza vaccination information from the American Academy of Pediatrics.

This National Immunization Awareness Month, prepare your pharmacy to offer important vaccines.

Xofluza is now the first single-dose oral medication for influenza approved for children aged less than 12 years.

Learn about the selected strains for this year’s flu season, flu vaccine recommendation changes, and newly licensed and forthcoming vaccine options

A study published in the International Journal of Infectious Diseases found flu vaccines reduced in-hospital deaths and recurrent hospitalizations for older hospitalized adults with cardiovascular disease.

Results indicate wide cross-protection against influenza A subtypes and strains in a young and aged mouse model.

Epic research suggests that like COVID-19, flu and other viral pneumonias can result in long-term symptoms like fatigue and brain fog. Why that might be is open question.

The preferential recommendation is built on research and real-world data

Multiple pharmaceutical companies are investigating the application of mRNA technology to develop vaccines that treat and prevent multiple conditions, from influenza to cancer and beyond.

Influenza is expected to make a comeback this year, and no one knows how severe it may be.

Seqirus’s FLUCELVAX® cell-based quadrivalent influenza vaccine has been approved to expand the age indication to children as young as 6 months of age by the US Food and Drug Administration.

According to new survey data from the National Foundation for Infectious Diseases, nearly 1 in 4 people at high risk for flu-related complications, such as pregnant women, did not plan to get vaccinated.

Novavax Incorporation announced on Monday that its combined flu and COVID-19 vaccine elicited working antibodies against the viruses in a preclinical study.

Although COVID-19 safety measures helped squash the number of influenza cases last season, pharmacists are revving up vaccination programs and testing.

A study highlighted at the 2021 ASCO Annual Meeting explored whether patients who received an influenza vaccine were at increased risk for immune-related adverse events from single-agent immune checkpoint inhibitors.

In a session from the PDS 2021 Virtual Super-Conference, experts discussed how POC testing capabilities enhance patient services and address antimicrobial resistance.

A recent study looked at the role of the influenza vaccine in COVID-19 susceptibility and severity

Preventive efforts, renewed interest in vaccinations drive milder flu season.

Peramivir injection (Rapivab; BioCryst) is approved for use in patients aged 6 months and older.